AMPH Q2 2018 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$860M

Q2 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$71M+9.0% YoY

Gross Profit

$26M36.8% margin

Operating Income

-$3M-4.0% margin

Net Income

-$3M-3.9% margin

EPS (Diluted)

$-0.06

QoQ Revenue Growth

+21.7%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

-$8M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$452M

Total Liabilities

$131M

Stockholders' Equity

$321M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$65M	+9.0%
Gross Profit	$26M	$27M	-2.2%
Operating Income	-$3M	$2M	-230.8%
Net Income	-$3M	$2M	-241.5%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$8M100%

Geographic Segments

U

$69M100%